Hologic, Inc. is a medical technology company dedicated to advancing women's health through early detection and treatment solutions. The company operates in four main segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health, offering a range of products that contribute significantly to its revenue . Hologic's offerings include advanced diagnostic assays, breast cancer care solutions, gynecological surgical products, and bone health assessment tools . In fiscal year 2023, the company reported total revenue of $4.03 billion, with each division achieving double-digit organic growth, excluding the impact of COVID-19 .
- Diagnostics - Offers a wide range of diagnostic products, including molecular diagnostic assays on systems like Panther and Panther Fusion, detecting infectious microorganisms, high-risk HPV strains, and other viruses. Includes the ThinPrep cytology system for cervical cancer screening and the Rapid Fetal Fibronectin Test for pre-term birth risk assessment .
- Breast Health - Provides solutions for breast cancer care, including 3D digital mammography systems, image analysis software, and minimally invasive breast biopsy systems, with strong revenue growth driven by increased gantry shipments and robust service revenue .
- GYN Surgical - Includes products like the MyoSure hysteroscopic tissue removal system and the NovaSure endometrial ablation system, with significant growth driven by MyoSure and Fluent systems .
- Skeletal Health - Offers products for bone health assessment, being the smallest contributor to overall revenue compared to the other segments .
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Stephen P. MacMillan ExecutiveBoard | Chairman, President, and CEO | Board Member at Illumina, Inc. | CEO since December 2013, Chairman since June 2015. Former CEO of Stryker Corporation and Pharmacia executive. | View Report → |
Brandon Schnittker Executive | Division President, GYN Surgical Solutions | None | Division President since January 2024. Former VP of Sales and Commercial Excellence for GYN Surgical Solutions. | |
Diana De Walt Executive | Senior Vice President, Human Resources | None | SVP since August 2024. Former SVP at Gen-Probe and HR consultant for diagnostics and biotech companies. | |
Essex D. Mitchell Executive | Chief Operating Officer (COO) | None | COO since January 2024. Former Division President, GYN Surgical Solutions. Previously held leadership roles at Stryker Corporation. | |
Jan Verstreken Executive | Group President, International | None | Group President since October 2020. Former Regional President, EMEA, Canada, and Latam. Extensive leadership experience at Teleflex. | |
Jennifer M. Schneiders Executive | President, Diagnostic Solutions | None | President since April 2023. Former VP of US Sales and Commercial Excellence for Diagnostics Solutions. | |
John M. Griffin Executive | General Counsel | None | General Counsel at Hologic. No additional details provided in the documents. | |
Karleen M. Oberton Executive | Chief Financial Officer (CFO) | Member of Merrimack College’s Leadership Council | CFO since August 2018. Former Chief Accounting Officer at Hologic and Senior Corporate Controller at Immunogen. | |
Mark Horvath Executive | Division President, Breast and Skeletal Health Solutions | None | Division President since January 2025. Former VP of Service Operations and Corporate VP of Global Services at Hologic. | |
Amy M. Wendell Board | Director | Board Member at AxoGen, Inc. and Baxter International Inc.; Chairman of Por Cristo | Director since December 2016. Former SVP of Strategy and Business Development at Covidien. | |
Charles J. Dockendorff Board | Director | Board Member at Boston Scientific, Haemonetics, and Keysight Technologies | Director since May 2017. Former CFO of Covidien plc. | |
Christiana Stamoulis Board | Director | EVP and CFO at Incyte Corporation | Director since November 2011. Extensive experience in strategy and corporate finance in the medical products field. | |
Ludwig N. Hantson Board | Director | None | Director since November 2018. Former CEO of Alexion Pharmaceuticals and Baxalta. | |
Martin Madaus Board | Director | Operating Executive at Carlyle Group; Board Member at Azenta, Quanterix, and Repligen | Director since December 2024. Former CEO of Ortho Clinical Diagnostics and Millipore Corporation. | |
Nanaz Mohtashami Board | Director | Managing Director at Russell Reynolds Associates | Director since September 2023. Leads the global Med Tech, Devices & Diagnostics Practice at Russell Reynolds. | |
Scott T. Garrett Board | Director | Senior Operating Partner at Water Street Healthcare Partners; Board Member at HCW Biologics, Inc. | Director since May 2013. Former Chairman and CEO of Beckman Coulter. | |
Stacey D. Stewart Board | Director | CEO of Mothers Against Drunk Driving (MADD); Board Member at PennyMac Mortgage Investment Trust | Director since January 2023. Former President & CEO of March of Dimes and U.S. President of United Way Worldwide. |
-
With the slowing of Panther placements after the pandemic , how do you plan to sustain growth in molecular diagnostics revenue, and can you provide more details on strategies to drive assay adoption without new instrument placements?
-
Given the upcoming launch of the new gantry in Breast Health and the potential impact on revenue in fiscal '25 , how are you addressing the risk of customers delaying purchases, and what steps are you taking to ensure revenue stability in this segment?
-
Regarding your recent acquisition of Gynasonix , can you elaborate on how the Sonata system complements your existing GYN Surgical portfolio without cannibalizing products like MyoSure, and what specific synergies do you expect to achieve?
-
With the reported transitory headwinds such as supply chain shortages and IV fluid issues , can you quantify the expected financial impact on fiscal '25, and what strategies are you implementing to mitigate these challenges?
-
In terms of capital allocation, given your recent M&A activities and share repurchase programs , how are you balancing investments in organic growth versus returning capital to shareholders, and what should investors expect in terms of future capital deployment?
Research analysts who have asked questions during HOLOGIC earnings calls.
Anthony Petrone
Mizuho Group
4 questions for HOLX
Casey Woodring
JPMorgan Chase & Co.
4 questions for HOLX
Jack Meehan
Nephron Research LLC
4 questions for HOLX
Patrick Donnelly
Citi
4 questions for HOLX
Andrew Cooper
Raymond James
3 questions for HOLX
Puneet Souda
Leerink Partners
3 questions for HOLX
Tejas Savant
Morgan Stanley
3 questions for HOLX
Vijay Kumar
Evercore ISI
3 questions for HOLX
Andrew Brackmann
William Blair & Company, L.L.C.
2 questions for HOLX
Lu Li
Scotiabank
2 questions for HOLX
Mason Carrico
Stephens Inc.
2 questions for HOLX
Michael Ryskin
Bank of America Merrill Lynch
2 questions for HOLX
Avery Kriss
Wolfe Research, LLC
1 question for HOLX
Connor McNamara
RBC Capital Markets
1 question for HOLX
Conor McNamara
RBC Capital Markets
1 question for HOLX
Dan Leonard
UBS Group AG
1 question for HOLX
Douglas Schenkel
Wolfe Research, LLC
1 question for HOLX
Doug Schenkel
Wolfe Research LLC
1 question for HOLX
Harrison Parsons
Stephens
1 question for HOLX
Jack Melick
Jefferies
1 question for HOLX
Joseph Conway
Needham & Company, LLC
1 question for HOLX
Kevin Joaquin
Evercore ISI
1 question for HOLX
Michael Matson
Needham & Company
1 question for HOLX
Navann Ty
BNP Paribas S.A.
1 question for HOLX
Navann Ty Dietschi
BNP Paribas
1 question for HOLX
Ryan Zimmerman
BTIG
1 question for HOLX
Tycho Peterson
Jefferies
1 question for HOLX
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Roche Diagnostics | A primary competitor in the Diagnostics business, offering a wide range of diagnostic products, including key raw materials for certain amplified NAT diagnostic assays. They are noted for their significant presence in the diagnostics market and are also a supplier to the company. , |
A primary competitor in the Diagnostics business, competing across various diagnostic market segments. | |
Siemens Healthineers | A primary competitor in the Breast & Skeletal Health business, offering large imaging solutions and competing in specific market segments such as breast biopsy and surgery. |
A primary competitor in the Breast & Skeletal Health business, offering imaging solutions and supplying membranes for the ThinPrep product line. They compete in breast health and skeletal health markets. , | |
A primary competitor in the GYN Surgical business, providing a full suite of surgical solutions and competing in procedures like hysterectomy. | |
A primary competitor in the GYN Surgical business, offering comprehensive surgical solutions and competing in procedures like hysterectomy. | |
F. Hoffmann-La Roche Ltd | The parent company of a supplier for certain key raw materials for amplified NAT diagnostic assays, and a direct competitor in the Diagnostics business. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Gynesonics, Inc. | 2025 | Completed on January 2, 2025, this acquisition was valued at approximately $350 million (subject to customary adjustments) and adds the SOMATEX system—a minimally invasive treatment tool for uterine fibroids—to Hologic’s GYN Surgical portfolio, supporting anticipated double-digit sales growth despite being slightly dilutive to non-GAAP EPS in 2025. |
Endomagnetics Ltd (Endomag) | 2024 | Closed on July 25, 2024 for roughly $310–313.9 million, this deal expands Hologic’s interventional breast business with UK-based breast surgery localization and lymphatic tracing technologies, with a preliminary purchase price allocation to intangible assets and goodwill. |
JW Medical Corporation | 2023 | Completed on July 3, 2023, the acquisition for $6.7 million secured a long-standing distribution network for Hologic’s Breast Health products in South Korea, with the bulk of the purchase price allocated to a customer relationship intangible asset with a 5-year life. |
Normedi Nordic AS | 2023 | Acquired on April 3, 2023 for $7.7 million (including a $1.1 million contingent consideration), this purchase bolstered Hologic’s presence in the Nordics for its Surgical products, with significant value allocated to a 5-year customer relationship intangible asset in addition to recorded goodwill. |
Bolder Surgical Holdings, Inc. | 2021 | Acquired on November 29, 2021 for $160.1 million, this transaction enhanced Hologic's surgical portfolio by adding energy vessel sealing devices and key technology platforms (JustRight and CoolSeal), with a detailed purchase price allocation including developed technology and customer relationships, along with non-deductible goodwill. |
Recent press releases and 8-K filings for HOLX.
- Hologic received FDA 510(k) clearance and CE marking in the EU for its Panther Fusion gastrointestinal bacterial and expanded bacterial assays, enabling rapid detection of pathogens such as Salmonella, Campylobacter, Shigella, and E. coli.
- The assays offer customizable mini-panels that can be run together or separately, streamlining laboratory workflows by reducing labor and speeding time to diagnosis versus traditional culture and microscopy methods.
- Testing is performed on Hologic’s Panther Fusion system, an add-on to the fully automated Panther platform, demonstrating seamless integration with existing laboratory automation.
- This regulatory approval follows Hologic’s strategic $159 million acquisition of Diagenode in 2021, which expanded the company’s proprietary real-time PCR testing portfolio.
- On July 15, 2025, Hologic entered into Refinancing Amendment No. 4 to its Amended and Restated Credit and Guaranty Agreement, replacing its existing term and revolving loans with $1,169,000,000 of 2025 Refinancing Term Loans and $1,000,000,000 of Revolving Credit Commitments, with Bank of America, N.A. as Administrative Agent.
- The amendment introduces customary affirmative and negative covenants, including maintenance of a minimum 3.00× Interest Coverage Ratio and maximum Total Net Leverage Ratios of 5.00:1.00 (stepping down to 4.50:1.00 over time), plus mandatory prepayment provisions on asset sales, debt issuances and insurance recoveries.
- The associated Pledge and Security Agreement was amended to secure the refinanced obligations with substantially all assets of Hologic and its Subsidiary Guarantors.
- The amendment is filed as Exhibit 10.1 to Hologic’s Form 8-K, dated July 18, 2025.
- Q2 guidance update: Hologic delivered revenue and EPS at the high end of its guidance range, though it adjusted its full-year EPS outlook downward by $0.10 due to anticipated tariff headwinds of $20-25 million per quarter related to Costa Rica manufacturing.
- US policy and domestic strategy: The company clarified that recent USPSTF guidelines supporting co-testing have eased concerns over cervical cancer screening tests, and its focus remains on leveraging its strong domestic presence, particularly in diagnostics, where favorable FX helped offset China headwinds.
- Capital deployment focus: Hologic is aggressively deploying free cash flow, with over $1.5 billion in cash and more than $700 million deployed in share repurchases, while also pursuing strategic M&A opportunities with recent acquisitions like Gynesonics and Endomag.
- Product and technology expansion: The firm continues to expand its Panther Fusion platform, enhancing its multiplexing capabilities in respiratory and STD testing, thereby reinforcing its dominant market position in these segments.
- Reported Q2 revenue of $1.005 billion (organic $980.0M), with GAAP diluted EPS of ($–0.08) and non-GAAP EPS of $1.03, ending the quarter at the high end of guidance .
- Achieved strong operating performance with GAAP operating margin (0.7%) and non-GAAP operating margin 30.0%, alongside a reduction in net leverage to 0.8x .
- Segment Performance: Diagnostics drove growth, the Skeletal business improved with easing supply constraints, while Breast Health revenue declined due to softer gantry sales .
- Generated $169.5 million in operating cash flow with robust liquidity and executed a strategic share repurchase of 3.0 million shares for $200 million .
- Provided updated guidance with Q3 revenue expected between $1 billion and $1.01 billion, and full-year 2025 guidance between $4,050–$4,100M in revenue with non-GAAP EPS of $4.15–$4.25 .